These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15377855)

  • 1. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.
    Fichtner I; Monks A; Hose C; Stevens MF; Bradshaw TD
    Breast Cancer Res Treat; 2004 Sep; 87(1):97-107. PubMed ID: 15377855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
    Leong CO; Suggitt M; Swaine DJ; Bibby MC; Stevens MF; Bradshaw TD
    Mol Cancer Ther; 2004 Dec; 3(12):1565-75. PubMed ID: 15634650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
    Leong CO; Gaskell M; Martin EA; Heydon RT; Farmer PB; Bibby MC; Cooper PA; Double JA; Bradshaw TD; Stevens MF
    Br J Cancer; 2003 Feb; 88(3):470-7. PubMed ID: 12569393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species.
    Bradshaw TD; Wren JE; Bruce M; Barrett DA; Leong CO; Gaskell M; Wright EK; Farmer PB; Henderson CJ; Wolf R; Stevens MF
    Pharmacology; 2009; 83(2):99-109. PubMed ID: 19088497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.
    Bradshaw TD; Westwell AD
    Curr Med Chem; 2004 Apr; 11(8):1009-21. PubMed ID: 15078163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
    Hose CD; Hollingshead M; Sausville EA; Monks A
    Mol Cancer Ther; 2003 Dec; 2(12):1265-72. PubMed ID: 14707267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
    Trapani V; Patel V; Leong CO; Ciolino HP; Yeh GC; Hose C; Trepel JB; Stevens MF; Sausville EA; Loaiza-Pérez AI
    Br J Cancer; 2003 Feb; 88(4):599-605. PubMed ID: 12592376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
    Brantley E; Trapani V; Alley MC; Hose CD; Bradshaw TD; Stevens MF; Sausville EA; Stinson SF
    Drug Metab Dispos; 2004 Dec; 32(12):1392-401. PubMed ID: 15355884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
    Kang HJ; Kim HJ; Kwon SH; Kang BD; Eling TE; Lee SH; Bae I
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):689-97. PubMed ID: 18074135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
    Bradshaw TD; Bibby MC; Double JA; Fichtner I; Cooper PA; Alley MC; Donohue S; Stinson SF; Tomaszewjski JE; Sausville EA; Stevens MF
    Mol Cancer Ther; 2002 Feb; 1(4):239-46. PubMed ID: 12467219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
    Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
    Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
    Brantley E; Antony S; Kohlhagen G; Meng L; Agama K; Stinson SF; Sausville EA; Pommier Y
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):62-72. PubMed ID: 16331501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
    Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
    Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
    Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
    Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines.
    Bradshaw TD; Stone EL; Trapani V; Leong CO; Matthews CS; te Poele R; Stevens MF
    Breast Cancer Res Treat; 2008 Jul; 110(1):57-68. PubMed ID: 17674193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of some new benzoxazole derivatives and investigation of their anticancer activities.
    Osmaniye D; Korkut Çelikateş B; Sağlık BN; Levent S; Acar Çevik U; Kaya Çavuşoğlu B; Ilgın S; Özkay Y; Kaplancıklı ZA
    Eur J Med Chem; 2021 Jan; 210():112979. PubMed ID: 33183865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro cytotoxicity of Phortress against colorectal cancer.
    Mukherjee A; Martin SG
    Int J Oncol; 2006 Nov; 29(5):1287-94. PubMed ID: 17016663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.